Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | PRKCA | P17252 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 4/20 | 0.43 |
| ▸ | CES1 | P23141 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL2123028 | 1.00 | TSHR (0.67) | TSHRLMNAPRKCAFAAHALDH1A1 | |
| Octane SCHEMBL10883673 | 1.00 | TSHR (0.67) | TSHRLMNAPRKCAFAAHALDH1A1 | |
| Hexane SCHEMBL372207 | 0.98 | TSHR (0.70) | TSHRLMNAPRKCAFAAHALDH1A1 | |
| Hexane SCHEMBL15841420 | 0.95 | TSHR (0.67) | TSHRLMNAPRKCAFAAHALDH1A1 | |
| Pentane SCHEMBL4454016 | 0.93 | TSHR (0.70) | TSHRLMNAPRKCAFAAHALDH1A1 | |
| 1-Heptanol SCHEMBL28115487 | 0.92 | TSHR (0.56) | TSHRLMNAPRKCAFAAHALDH1A1 | |
| 2-Nonanone SCHEMBL15841421 | 0.90 | LMNA (0.63) | TSHRLMNAPRKCAFAAHALDH1A1 | |
| 1-Pentanol SCHEMBL11376862 | 0.89 | TSHR (0.58) | TSHRLMNAPRKCAFAAHALDH1A1 | |
| Palmitic Acid SCHEMBL28655448 | 0.88 | GPR84 (0.63) | TSHRLMNAALDH1A1MAPTMEN1 | |
| Myristic Acid SCHEMBL28574672 | 0.88 | GPR84 (0.63) | TSHRLMNAALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865769-A | Separation method of n-heptane-isopropyl acetate-toluene | 扬州贝尔新环境科技有限公司 | 2024-04-12 | — | — | CN | claimed |
| WO-2023051753-A1 | PREPARATION METHOD FOR ROCK INHIBITOR, INTERMEDIATE THEREOF AND PREPARATION METHOD FOR INTERMEDIATE | 武汉朗来科技发展有限公司 | 2023-04-06 | — | — | WO | claimed |
| CN-115894463-A | Preparation method of ROCK inhibitor, intermediate thereof and preparation method of intermediate | 武汉朗来科技发展有限公司 | 2023-04-04 | — | — | CN | claimed |
| US-20220289587-A1 | A NOVEL POLYMORPH AND USES THEREOF | PROCYPRA THERAPEUTICS, LLC (US) | 2022-09-15 | — | — | US | claimed |
| EP-4025223-A1 | A NOVEL POLYMORPH AND USES THEREOF | Procypra Therapeutics, LLC (US) | 2022-07-13 | — | — | EP | claimed |
| WO-2021046092-A1 | A NOVEL POLYMORPH AND USES THEREOF | PROCYPRA THERAPEUTICS, LLC (US) | 2021-03-11 | — | — | WO | claimed |
| US-20170362183-A1 | PYRAZOLYL CARBOXYLIC ACID AND PYRAZOLYL UREA DERIVATIVE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | claimed |
| CN-106397515-A | An improved sofosbuvir preparation method | 广东东阳光药业有限公司 | 2017-02-15 | — | — | CN | claimed |
| CN-103664837-B | A kind of preparation method of high purity Cabazitaxel intermediate | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2016-01-20 | — | — | CN | claimed |
| WO-2024116127-A1 | VENGLUSTAT IN COMBINATION WITH A STRONG OR MODERATE INHIBITOR OF CYP3A4 | GENZYME CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-11958864-B2 | Tetracyclic heterocycle compounds useful as HIV integrase inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-04-16 | — | — | US | disclosed |
| US-11958845-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| EP-4349408-A2 | METHODS FOR TREATING PROTEINOPATHIES | Genzyme Corporation (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-1216532-A | Method of preparing phosphodiesterase IV inhibitors | MERCK & CO INC (US) | 1999-05-12 | — | — | CN | disclosed |
| US-5728838-A | REDUCTIVE ALKYLATION AND REMOVAL OF SULFINYL GROUPS | MERCK & CO., INC. (US) | 1998-03-17 | — | — | US | disclosed |
| CN-1152920-A | Palladium-Catalyzed Ring Closure of Triazolyl Tryptamine | MERCK & CO INC (US) | 1997-06-25 | — | — | CN | disclosed |
| EP-0763032-A1 | PALLADIUM CATALYZED RING CLOSURE OF TRIAZOLYL TRYPTAMINE | MERCK & CO. INC. (US) | 1997-03-19 | — | — | EP | disclosed |
| US-5567824-A | CATALYZING THE CYCLIZATION IN PRESENCE OF A SOLVENT AND A PROTON ACCEPTOR | MERCK & CO., INC. (US) | 1996-10-22 | — | — | US | disclosed |
| WO-1995032197-A1 | PALLADIUM CATALYZED RING CLOSURE OF TRIAZOLYL TRYPTAMINE | MERCK & CO., INC. (US) | 1995-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958864-B2 | Tetracyclic heterocycle compounds useful as HIV integrase inhibitors | CDKN1A, TYMP, TYMS | TSHR 3580/4885LMNA 2508/4885PRKCA 3261/4885 |
| US-20170362183-A1 | PYRAZOLYL CARBOXYLIC ACID AND PYRAZOLYL UREA DERIVATIVE COMPOUNDS | UROD, PEPD, CMPK1 | TSHR 3601/4885LMNA 4266/4885PRKCA 941/4885 |
| US-11958845-B2 | Heterocyclic compound | HDAC6, HDAC1, HDAC5 | TSHR 3746/4885LMNA 3611/4885PRKCA 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.